Active	Status	Sponsor type	Region	Phase	Filter
8 Active 0 Inactive 8 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Calles, Antonio
LUPER, NCT04358237 / 2019-002261-35: Lurbinectedin (PM01183) Combined With Pembrolizumab in Small Cell Lung Cancer.	Active, not recruiting	1/2	28	Europe	Lurbinectedin, PM01183, Zepsyre, Pembrolizumab, Keytruda	Antonio Calles Blanco, MedSIR, PharmaMar, Merck Sharp & Dohme LLC	Small Cell Lung Carcinoma	09/23	03/25
RAMP 203, NCT05074810: Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients	Recruiting	1/2	153	Europe, US	avutometinib and sotorasib, AMG 510, LUMAKRAS™, VS-6766, avutometinib and sotorasib and defactinib, VS-6063	Verastem, Inc., Amgen	Non Small Cell Lung Cancer, KRAS Activating Mutation	09/25	04/27
METex14, NCT04868877 / 2021-000203-20: Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination	Recruiting	1/2	576	Europe, US, RoW	MCLA-129, bispecific, Osimertinib, Tagrisso, Chemotherapy	Merus N.V.	Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer	03/26	03/27
ARROS-1, NCT05118789 / 2021-002477-26: A Study of NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement	Recruiting	1/2	359	Europe, Canada, Japan, US, RoW	NVL-520	Nuvalent Inc., Nuvalent, Inc.	Locally Advanced Solid Tumor, Metastatic Solid Tumor	10/25	10/26
ALKOVE-1, NCT05384626 / 2022-000122-21: A Study of NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation	Recruiting	1/2	470	Europe, Canada, Japan, US, RoW	NVL-655	Nuvalent Inc., Nuvalent, Inc.	Locally Advanced Solid Tumor, Metastatic Solid Tumor	02/26	03/26